FM
ACRS icon

Frazier Management’s Aclaris Therapeutics ACRS Stock Holding History

Frazier Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-408,329
Closed -$5.94M – 3
2021
Q4 		$5.94M Hold
408,329
– – 0.46% 36
2021
Q3 		$7.35M Buy
408,329
+37,596
+10% +$603K 0.59% 30
2021
Q2 		$6.51M Sell
370,733
-325,267
-47% -$7.39M 0.6% 23
2021
Q1 		$17.5M Buy
+696,000
New +$13.6M 1.41% 15

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Frazier Management's ACRS Position: Q1 2022 in Review

Frazier Management sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 408,329 shares — an estimated $5.94M sold.

Frazier Management first reported a position in ACRS in Q1 2021 and held it in 4 quarters. The position peaked at $17.5M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Frazier Management reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 408,329 Aclaris Therapeutics shares in Q1 2022, an estimated $5.94M.
  • Frazier Management first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 4 quarters.
  • Frazier Management's Aclaris Therapeutics position peaked at $17.5M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.